Subscribe

0

  • Sign in with Email

By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.

Don’t have an account? Signup

  • Bookmarks
  • My Profile
  • Log Out
  • NEWS
  • POLICIES
  • MSME OPPORTUNITIES
  • BANKING & FINANCE
  • TECHNOLOGY FOR SMES
  • SECTORS
  • GLOBAL
  • Investment
  • LEGAL
  • KNOWLEDGE QUEST
  • Future Ready Forum 2025
  • Ek Nayi Udaan
  • Future Ready Summit 2024
  • ADVERTISE WITH US
ad_close_btn
  • News
  • Policies
  • Banking & Finance
  • MSME Opportunities
  • Web Stories
  • InFocus
  • Technology For SMEs
  • Sectors
  • Global
  • Fashion

Powered by :

You have successfully subscribed the newsletter.
InFocus Corporate

ED Asks Gland Pharma to Transfer B. Ramlinga Raju's Shares to Escrow Account

Srinivas Sadhu, MD and CEO of Gland Pharma, told reporters during a virtual press conference that they are following the directions of the ED. He clarified that these shares are not part of the IPO.

author-image
SMEStreet Edit Desk
05 Nov 2020 09:10 IST

Follow Us

New Update
Ramlinga Raju, Satyam, ED,

Gland Pharma will transfer six million shares owned by companies promoted by Satyam Computers' B. Ramalinga Raju and his kin to an escrow account on the direction of the Enforcement Directorate (ED), a top company official said.

The development comes ahead of Gland Pharma's Initial Public Offer (IPO) announcement.

Srinivas Sadhu, MD and CEO of Gland Pharma, told reporters during a virtual press conference that they are following the directions of the ED. He clarified that these shares are not part of the IPO.

The ED had attached the shares held by Raju and his kin after multi-crore scam broke out in Satyam Computer Services Ltd in 2009. It had directed Gland Pharma not to transfer, dispose, remove, part with or otherwise deal with them in any manner until further instruction from it.

With the Hyderabad-based pharma company, controlled by Chinese pharmaceutical giant Shanghai Fosun Pharma, planning an IPO, the ED directed it to transfer the shares.

Gland Pharma on Wednesday announced that IPO to raise almost Rs 6,500 crore will open on November 9. This is one of the largest IPOs in India's pharmaceutical sector. The firm has set a price band of Rs 1,490-1,500 per share (face value of Re 1).

At least 10 firms owned by Raju and his family members held 600,000 shares with Rs 10 face value. They subsequently became six million with each share's face value of Rs 1.

The shares attached by ED are 3.87 per cent of the pre- offer paid-up equity share capital of the company. The company made it clear that the 10 firms which hold the shares are not related to Gland Pharma or its promoters, promoter group, directors or key managerial personnel.

Sadhu does not foresee any impact on the company in view of the restrictions being imposed by India on Chinese companies. He said Gland Pharma into healthcare sector and it grew under different investors.

"We don't foresee any impact," he said and pointed out that Gland Pharma sell its products to several companies around the world, mostly in the US.

It was in 2017 that Fosun Pharma had acquired 74 per cent stake in Gland Pharma, which was founded by P.V.N. Raju in 1978.

ED Ramlinga Raju Gland Pharma Satyam
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news
logo

Related Articles
Read the Next Article
Latest Stories
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news

Latest Stories
Latest Stories
    Powered by


    Subscribe to our Newsletter!




    Powered by
    Select Language
    English

    Share this article

    If you liked this article share it with your friends.
    they will thank you later

    Facebook
    Twitter
    Whatsapp

    Copied!